Eva Havrdová - Concepedia

Author

Eva Havrdová

Also Known As

Dana Horakova, David Doležil, David Macmanus, E Havrdova, E Havrdová, E Kubala Havrdova, E. HAVRDOVÁ, E. Havrdova, E. Havrdová, E. K. Havrdova

740

Publications

40K

Citations

H-Index

164

Concepts

All Affiliations

Charles University The University of Melbourne University Hospital of Basel The Royal Melbourne Hospital General University Hospital in Prague

About

Eva Havrdová is an author at Charles University specializing in medicine, multiple sclerosis, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	73	19.4K
2	Public Health	9	9	905
3	Health Sciences	8	8	10.3K
4	Social Sciences	3	3	93
5	Allergy	3	3	304

Eva Havrdová

239

Publications

35.3K

Citations

H-Index

Page 1

	Year	Citations
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria Chris H. Polman, Stephen C. Reingold, Brenda Banwell, Annals of Neurology Mcdonald CriteriaNeurological DisorderMedicineNeuroepidemiologyDiagnostic Criterion	2011	9.7K
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Chris H. Polman, Paul O’Connor, Eva Havrdová, New England Journal of Medicine	2006	3.3K
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis Robert J. Fox, David H. Miller, J. Theodore Phillips, New England Journal of Medicine	2012	1.3K
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold, The Lancet RheumatologyRelapsing-remitting Multiple SclerosisImmunologyClinical TrialsTreatment Option	2012	1.2K
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Alasdair Coles, Cary Twyman, Douglas L. Arnold, The Lancet ImmunologyClinical TrialsNeurological ProgressDisease-modifying TherapyMultiple Sclerosis	2012	1.2K
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis Xavier Montalbán, Ralf Gold, Alan J. Thompson, Multiple Sclerosis Journal	2018	664
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis J William L Brown, Alasdair Coles, Dana Horáková, JAMA	2019	511
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Ludwig Kappos, Ralf Gold, David H. Miller, The Lancet Relapsing-remitting Multiple SclerosisMedicineClinical NeurologyClinical TrialsNeurological Progress	2008	477
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Eva Havrdová, Steven Galetta, Michael Hutchinson, The Lancet Neurology RheumatologyRadiological Disease ActivitySystemic SclerodermaMedicineImmunology	2009	470
Defining secondary progressive multiple sclerosis Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Brain Neurological DisorderDisabilityClinical NeurologyNeurological ProgressNeurological Rehabilitation	2016	401

Page 1